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Introduction
Immunoglobulin E (IgE) activates mast cells by binding to its high affinity receptor Fcε receptor-1 (FcεR1). This activity of IgE is essential to allergic responses (1) , such as asthma. Recent studies demonstrated that IgE also activates macrophages and T cells (2, 3) . All these IgE-targeting cells play detrimental roles in obesity and diabetes (4) (5) (6) , suggesting the participation of IgE in these metabolic diseases. Although the direct role of IgE in obesity and diabetes remains untested, asthma associates with increased plasma IgE (7) and acts as an important risk factor of obesity and diabetes. Of 4,773 subjects aged 20 and older randomly selected from 10,348 individuals from 2005 to 2006 in the National Health and Nutrition Examination Survey (NHANES) in the United States, IgE concentrations correlated positively with obesity risk but not insulin resistance in asthmatic patients (8) . Of 4,321 children aged 2 to 19 from the same population, obese and overweight children had higher plasma total IgE levels, driven largely by allergic sensitivity to foods (9) . A respective study of 246 adults with asthma and other atopic disorders revealed that asthmatic patients had higher body mass indices (BMI) than nonasthmatics. Obesity associated with increased serum IgE among those patients (10) . Yet in a population study of 666 patients with severe asthma, plasma IgE levels correlated negatively with BMI (11) . These studies therefore do not prove the direct participation of IgE in body weight gain. Previous studies investigated IgE in patients and animals with diabetes. A linear regression analysis of a population study of 340 patients aged 55 to 75 revealed a positive correlation between plasma IgE and type-2 diabetes mellitus and prediabetes status. Ordinal logistic regression demonstrated that plasma IgE correlates with the incidence of type-2 diabetes before and after adjusting for common diabetes risk factors (12, 13) . In non-obese diabetic (NOD) mice, anti-FcεR1 antibody therapy activated basophils and MCs, but delayed type 1 diabetes (14) . These observations from diabetic patients and mice highlight the role of IgE in diabetes.
This study design was twofold: to test the direct role of IgE in obesity and diabetes using FcεR1-deficient Fcer1a -/mice in diet-induced obese and diabetic mice;
and to understand the molecular and cellular mechanism by which this immunoglobulin molecule contributes to these metabolic diseases.
Materials and Methods

Patients
A random selection from a bariatric surgery program from the Institute of Cardiometabolism and Nutrition (ICAN), Pitié-Salpêtrière Hospital (Paris, France) yielded a cohort of 50 Caucasian women with morbid obesity. These patients met the criteria for bariatric surgery (BMI ≥ 40 kg/m 2 , or ≥ 35 kg/m 2 with at least one comorbidity: hypertension, type-2 diabetes, dyslipidemia, or obstructive sleep apnea syndrome), but without allergic or autoimmune diseases or anti-allergy and antiautoimmunity medications that may affect plasma IgE levels. Subjects had stable weights (±3 kg) for at least 3 months before the surgery. Of the 50 patients, 18 (36 %) had type 2 diabetes as defined by a fasting glycemia >7 mmol/L and/or the use of an anti-diabetic drug. The ethics committees of the CPP Ile de France 1 (number 0611351) approved the clinical investigations. All subjects gave written informed consent. Spearman's correlation test helped test the correlation between plasma IgE concentration and clinical and biological parameters at baseline. Patient body composition was determined by dual-energy X-ray absorptiometry (DEXA, Hologic, Bedford, MA). Blood samples were obtained before the bariatric surgery after 12 hours of fasting to measure total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, insulin, glucose, hemoglobin (HbA1c), leptin, adiponectin, inflammatory markers (highly sensitive C-reactive protein (hs-CRP) and interleukin-6 (IL6), and IgE as previously described (12, 13, 15, 16) .
Mice
We used C57BL/6 (Jackson Laboratory, Bar Harbor, ME) and Fcer1a -/mice (C57BL/6, N9) (2, 3) . All mice used in this study were littermates. Males (or female) mice at 6 weeks of age from each group were fed a high-fat diet (HFD, D12492: 60 kcal% fat, Research Diets Inc. New Brunswick, NJ) for 17 weeks. Mouse body weight was monitored weekly. After 17 weeks on a HFD, mouse total body fat and lean masses were assessed by dual energy X-ray absorptiometry (DEXA; PIXImus, Fitchburg, WI). For calorimetric analysis, these mice were placed individually in an indirect open circuit calorimeter (Oxymax System; Columbus Instruments, Columbus, OH). Oxygen and carbon dioxide concentrations by volume were monitored at the inlet and outlet parts of a partially sealed chamber, through which a known flow of ambient air was forcibly ventilated. The concentration difference measured between the parts was used to compute oxygen consumption (VO 2 ) and carbon dioxide production (VCO 2 ). The consumption and production information were presented in units of ml/kg/h and normalized to 25 °C and 760 mmHg. Food intake was investigated by using the Oxymax Feed Scale Device (Columbus Instruments) for three continuous days and data were presented as the average food intake per day of the last two days without considering the first day acclimation period. The physical activity of the mice was monitored with OPTO-M3 Activity Application Device (Columbus Instruments). The movements (other than scratching, grooming, digging, etc.) of each animal were determined by infrared beams in x, y, and z axes. After 17 weeks on a HFD, an intraperitoneal glucose tolerance test (1.5 g glucose/kg body weight) and an insulin tolerance test (ITT) (1.5 U/kg body weight) were also performed after an overnight (16 hours) and daytime 5-hour fast, respectively. Mice were sacrificed and fat tissue was collected. Mice were bred and maintained according to 
Islet isolation and glucose-stimulated insulin secretion (GSIS) by islets
Islets were isolated from 2-month-old male C57BL/6J mice (Jackson Laboratory) by the intraductal collagenase digestion method, as described previously (17) . For GSIS assay, after culturing for 12 hours in RPMI 1640 medium containing 5.6 mM glucose and supplemented with 10% fetal calf serum, ten size-matched islets were incubated at 37°C for 1.5 hours in Krebs-Ringer bicarbonate buffer containing 2.8, 8.3 or 22.2 mM glucose with or without IgE (0.01, 0.1, 1, 10, 100 µg/ml). The insulin levels in the culture media were measured using an insulin ELISA kit (Crystal Chem Inc., Downers Grove, IL).
FcεR1α mRNA levels were measured in total RNA extracted from 50 islets that were incubated at 37°C for 24 hours in RPMI 1640 medium containing 5.6 mM glucose with 10% fetal calf serum in the presence or absence of IgE (0.01, 0.1, 1, 10, 100 µg/ml ).
Each quantitative reaction was performed in duplicate.
Quantitative real-time PCR
Total RNA was extracted from WAT, 3T3-L1 cells, bone marrow-derived macrophages, or islets using a Qiagen RNA extraction kit (Qiagen, Valencia, CA). Quantified total RNA using Nanodrop 2000 (Thermo Fisher Scientific Inc., Waltham, MA) was transcribed into first strand cDNA using Superscript First Strand kit (Life Technologies).
Real-time PCR (RT-PCR) was performed using SYBR green super mix (Bio-Rad) in
Bio-Rad iCycler iQ to determine the mRNA levels of C/EBPα, PPARγ, and three FcεR1 chains (α, β, and γ) using 36B4 (acidic ribosomal phosphoprotein PO) and β-actin as internal controls to normalize gene expression. RT-PCR data was analyzed based on delta delta CT calculation and presented as the fold of change obtained from the value of 2^(-∆∆CT). All RT-PCR primer sequences are listed in Supplementary Table 1 . Supplementary Table 2 .
Immunoblotting and immunohistochemistry
ELISA
ELISA determined plasma IL6 (eBioscience), monocyte chemotactic protein-1 (MCP-1) (eBioscience), IgE (BD Biosciences, Bedford, MA), insulin (Crystal Chem Inc.) and serum amyloid A (Life Technologies), according to the manufacturers' instructions.
2-Deoxyglucose (2DG) uptake assay
Preadipocyte 3T3L1 cells were differentiated to adipocytes in a 48-well plate with and without IgE (0, 1, 10, 50 µg/ml). After 2 days, glucose uptake was performed using a 2deoxyglucose (2DG) uptake measurement kit (Cosmo Bio Co. Ltd., Tokyo, Japan), according to manufacturer's instructions.
siRNA transfection
Both FcεR1α and scramble control siRNAs (100 nM, Santa Cruz) were transfected to preadipocyte 3T3-L1 cells in a 12 well-plate after electroporation with an Amaxa® Cell Line Nucleofector® Kit (Lonza, Allendale, NJ). After 24 hours, cells were differentiated in an induction medium and cultured for 4 days followed by starvation and stimulation with 25 µg/ml IgE for 10 min. Cells were lysed for protein analysis.
Cell Cytotoxicity assay
Preadipocyte 3T3-L1 cells were differentiated to adipocytes on an 8-well chamber slide or a 96-well plate with and without IgE (50 µg/ml) for 2-8 days before TUNEL staining 
Oil-red O staining
Differentiated 3T3-L1 cells with and without IgE (50ug/ml) in a 96-well plate were fixed with 10% formalin for one hour, washed with 100% propylene glycol, and stained with 0.5% oil-red O for 4 hours. This procedure was followed by washing with 85% propylene glycol. For quantitative analysis, stained cell layers were extracted with isopropanol and measured at OD 510 nm .
Statistical analysis
All human data are expressed as means ± SD. Correlation analyses between IgE concentration and clinical parameters were performed using Spearman's correlation.
Regression plots were built after log transformation of IgE values for normalization purpose. All P-values are two-sided, and P-values of <0.05 were considered to be statistically significant. All analyses were performed using R software, version 3.0.1. All mouse data were expressed as mean ± SEM. Due to our small sample sizes and often skewed data distributions, we performed a pairwise non-parametric Mann-Whitney test followed by Bonferroni corrections to examine the statistical significance.
Results
Inverse correlation between human plasma IgE and obesity
Data obtained from the 50 obese women (age: 42±11 years, BMI: 50.67±8.26 kg/m 2 ) showed that serum IgE correlated negatively with BMI (P=0.018, Rho= -0.33) ( Figure 1A ), body weight (P= 0.016, Rho= -0.34) ( Figure 1B) , and fat mass (P=0.023, Rho= -0.34) ( Figure 1C ). Fasting glycemia, insulin, HbA1C, triglyceride, high-density lipoprotein HDL, ApoA1, ApoB, aspartate amino-transferase AST, alanine aminotransferase ALT, γ-glutamyl transpeptidase γGT, leptin, adiponectin, IL6, and hs-CRP did not associate with IgE levels. Only total cholesterol correlated positively with IgE (P= 0.028, Rho=0.31) ( Supplementary Table 3 ). Of the 50 severely obese patients, 18 had type 2-diabetes. Diabetic obese patients were significantly older and exhibited a higher BMI, fasting glycemia, fasting insulin, and HbA1C as expected. These patients also had lower HDL and higher triglyceride, ALT, γGT, IL6 and hs-CRP levels than nondiabetic obese patients. Diabetic and non-diabetic obese patients did not exhibit significantly different plasma IgE levels, however (data not shown).
FcεR1 deficiency increases body weight gain, but improves glucose tolerance in mice
This study monitored the body weight and included glucose and insulin tolerance assays in both male and female WT and FcεR1-deficient Fcer1a -/mice. Male ( Figure   2A ) or female (data not shown) FcεR1-deficient Fcer1a -/mice gained significantly more body weight than WT control mice on a HFD. Fcer1a -/mice consumed significantly more food and gained more lean and fat mass, as determined by DEXA analysis ( Figure   2B ). Fcer1a -/mice demonstrated significantly improved glucose tolerance but exhibited no difference in insulin tolerance when compared to WT control mice ( Figure 2C ), suggesting that Fcer1a -/mice had improved glucose metabolism but a similar degree of insulin resistance to that of WT mice. Consistently, overnight-fasted Fcer1a -/mice exhibited elevated glucose-induced insulin release, which showed no significant difference from WT mice at 90 minutes after the first glucose stimulation ( Figure 2D ).
Islets from WT mice released insulin responding to glucose in a dose-dependent manner, but IgE did not affect islet insulin production at any tested doses of up to 100 µg/mL expression on islets than that on bone marrow-derived macrophages ( Figure 2F ). Non-fasted WT and Fcer1a -/mice on a HFD showed no difference between the basal levels of plasma IgE or insulin ( Figure 2G ). WAT from Fcer1a -/mice, however, had significantly lower IgE levels than WT mice ( Figure 2H ). Although a direct comparison remains impossible, WAT milieu may have much higher IgE concentrations (about 1,600 ng per mg WAT protein from WT mice) than the plasma (about 150 ng/mL from WT mice). Consistent with increased body weight gain, Fcer1a -/mice had higher plasma serum amyloid A (SAA), IL6, and MCP-1 than WT control mice after consuming a HFD, although the difference in MCP-1 levels did not reach statistical significance ( Figure 2I ).
Yet data showed significantly fewer Mac2-positive macrophages in both subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) from Fcer1a -/mice than those from WT control mice ( Figure 3A/3B ). VAT from Fcer1a -/mice also contained fewer CD3 + T cells than VAT from WT mice ( Figure 3C ). TUNEL staining also revealed significantly fewer apoptotic cells in WAT from Fcer1a -/mice than in WT mice ( Figure   3D ), which possibly contributed to increased body weight gain and body fat mass in Fcer1a -/mice (Figure 2A/2B ). Metabolic characterization demonstrated that Fcer1a -/mice on a HFD had lower O 2 consumption and CO 2 production than WT control mice ( Figure 3E/3F ), although the two groups did not reach statistical significance in regards to respiratory exchange ratio (RER) and body heat ( Figure 3G/3H ). Although Fcer1a -/mice showed more food intake than WT control mice ( Figure 2B ), their plasma leptin levels and WAT adipocyte sizes did not significantly differ ( Figure 3I/3J ). Reduced energy expenditure in HFD-fed Fcer1a -/mice ( Figure 3E /3F) may contribute to increased body weight gain in these mice (Figure 2A ). Immunoblot analysis demonstrated much lower UCP1 expression in BAT from Fcer1a -/mice than that from WT control mice ( Figure 3K ).
FcεR1 deficiency in mice affects the expression of molecules involved in WAT adipogenesis, apoptosis, and glucose uptake
Immunoblot analysis ( Figure 4A ) and immunostaining ( Figure 4B Figure 4H ), which might also contribute to increased fat mass and body weight gain in Fcer1a -/mice (Figure 2A/2B ). Improved glucose tolerance and increased release of plasma insulin after a glucose challenge in Fcer1a -/mice ( Figure  2C /2D) might also associate with increased PPARγ expression (26, 27) . Immunoblot analysis revealed significantly increased Glut4 expression in WAT from Fcer1a -/mice ( Figure 4I ).
IgE suppresses adipogenesis in mice
Increased fat mass in Fcer1a -/mice (Figure 2A 
IgE activity on 3T3-L1 adipocyte apoptosis and glucose uptake
Increased fat mass in Fcer1a -/mice ( Improved glucose tolerance in Fcer1a -/mice ( Figure 2C ) increased insulin secretion to the plasma from Fcer1a -/mice after a glucose challenge ( Figure 2D ), and increased Glut4 expression in WAT from Fcer1a -/mice ( Figure 4I) , which suggests the participation of IgE in inhibiting glucose uptake. This study tested this hypothesis in 3T3-L1 cells after 2 days differentiation, when 3T3-L1 increased FcεR1 expression ( Figure   5A /5B) but IgE treatment did not induce 3T3-L1 apoptosis ( Figure 6A ) to interfere with glucose uptake. While preadipocytes took up 2-deoxy-D-glucose (2DG) at baseline, as determined by measuring intracellular hexokinase-phosphorylated 2DG-6-phosphate (2DG6P) (29) , differentiated 3T3-L1 cells showed a significant increase in glucose uptake. IgE treatment inhibited glucose uptake in a concentration-dependent manner ( Figure 6F) . A reduced expression of glucose transporters likely mediated IgE-suppressed glucose uptake. In differentiated 3T3-L1 cells, IgE reduced the expression of Glut4 and its upstream signaling molecule p-AKT ( Figure 6G ). In differentiated 3T3-L1 cells, the silencing of FcεR1 expression with its siRNA, as confirmed by FcεR1 immunoblot analysis, increased the expression of both Glut4 and p-AKT, compared with those transfected with scrambled control siRNA ( Figure 6H ). This result establishes that IgE suppresses glucose uptake by reducing the expression of glucose transporters.
Discussion
This study revealed the dual participation of IgE action in obesity and diabetes, which remained consistent to observations from several human studies. Plasma IgE levels correlated negatively with BMI among patients with severe asthma (11) . Data showed that plasma IgE levels also correlated negatively with body weight, BMI, and fat mass among severely obese women, although the current study observed a relatively small cohort with a power of 0.691 compared with other similar studies (11) . However, this is the first correlation study linking IgE to obesity without the confounding from asthma or other allergic or autoimmune diseases. These human studies point to the role of IgE in modulating obesity. We reported previously that human plasma IgE correlated positively with type-2 diabetes (12, 13) . Interruption of IgE action with an anti-FcεR1 antibody delayed the onset of type-1 diabetes in mice (14) , suggesting IgE increases plasma glucose levels.
This study also demonstrated that the interruption of IgE action in Fcer1a -/mice increased food intake and reduced energy expenditure (O 2 consumption and CO 2 production), as reflected by reduced UCP1 expression in BAT from the Fcer1a -/mice, without exhibiting significant changes in RER and body heat. These physiological changes may contribute to increased body weight gain in these mice. Although previous data suggest that high RER and body heat reduce body weight, the presence of diabetes may affect such values. In obese humans, non-diabetic patients have lower RMR than diabetic patients (30) . Increased body weight but improved glucose tolerance in Fcer1a -/mice may trigger insignificant differences in RMR and body heat between WT and Fcer1a -/mice, although this hypothesis merits further investigation. At the molecular and cellular levels, however, this study proposed two possible mechanisms by which IgE reduced fat mass; one is the C/EBPα and PPARγ pathway. Activation of C/EBPα is a prerequisite for PPARγ activation (28) . Several signaling pathways can activate C/EBPα, including the MAP kinase (e.g. p38 and ERK1/2) (31), the cAMP-associated protein kinase-A pathway (32) , and the AKT pathway (19, 20) . Activation of IgE receptor FcεR1 activates the MAP kinase pathway, but suppresses AKT activation (18) . This study found that WAT from Fcer1a -/mice showed increased p-AKT, C/EBPα, and PPARγ, supporting a negative action of IgE on AKT activation, downstream C/EBPα and PPARγ (19, 20) , and consequent adipocyte differentiation (21, 22) . The second mechanism by which IgE can influence obesity involves its activity in promoting the apoptosis of adipocytes while preadipocytes were fully protected. IgE can furnish survival signals to In contrast to the inhibitory effect of IgE on obesity, IgE promotes experimental type 2 diabetes. IgE-suppressed p-AKT may directly impair the expression and distribution of glucose transporters, such as Glut 4 (36, 37) , and indirectly via reduced PPARγ expression and activation (38) . Therefore, in 3T3-L1 cells, IgE reduced p-AKT and Glut4 expression and FcεR1 knockdown by its siRNA increased p-AKT and Glut4 expression, all of which may explain concentration-dependent suppression of glucose uptake in 3T3-L1 cells by IgE. A similar pattern occurred in vivo. FcεR1 deficiency increased WAT Glut4 expression. These observations may explain why Fcer1a -/mice had improved glucose tolerance and glucose-induced insulin release. Figure 7 summarizes our hypothesis.
Several questions remain unresolved. Fcer1a -/mice consumed more food and had lower levels of energy expenditure and BAT expression of UCP1 than WT control mice. Although these observations may explain why Fcer1a -/mice gained more body weight than WT mice, the mechanism by which IgE activity controls food uptake and energy expenditure remains unknown. Prior studies showed that leptin infusion augmented plasma IgE levels in allergen-challenged mice (39) , but the absence of IgE receptor FcεR1 did not affect plasma leptin levels. Therefore, IgE may control food uptake and energy expenditure with mechanisms other than leptin. For example, gut microbiota-associated metabolic endotoxemia and inflammation impair food uptake (40, 41) . IgE may reduce food uptake by inducing gut inflammation (42, 43) , although this study did not test this hypothesis. We further found that Fcer1a -/mice exhibited improved glucose tolerance and glucose-induced insulin secretion, but these mice showed similar degrees of insulin resistance and similar basal levels of plasma insulin to those from WT control mice. This study did not reveal a direct participation of IgE in suppressing glucose-induced insulin secretion in isolated islets, suggesting that elevated glucose-induced insulin secretion in Fcer1a -/mice indirectly participated in IgE (44, 45) .
All in vitro experiments in this study used IgE at concentrations (10~100 µg/mL) much higher than its physiological concentrations in human or mouse plasma (100~400 ng/mL). At 10 µg/mL, IgE showed a negligible effect in suppressing adipogenesis and weak suppression of glucose uptake. Therefore, this study used 50 µg/mL IgE to demonstrate inhibition of 3T3-L1 cell adipogenesis, promoting adipocyte apoptosis, and suppressing Glut4 expression and glucose uptake. The physiological relevance of these in vitro experiments remains a key question. As described in our prior studies of atherosclerosis and AAAs (3, 4) , low plasma IgE levels may not necessarily reflect the actions of tissue IgE in situ. The tissue milieu may harbor higher levels of IgE than previously surmised. This possibility remains consistent to our observation that each milligram of WAT extract from DIO mice contained about 1,600 ng of IgE.
This study provides the first direct evidence of IgE participation in obesity and diabetes, although many observations still remain incompletely understood. As atopic diseases can affect certain disadvantaged populations who remain particularly vulnerable to obesity and diabetes (8-11, 46, 47) 
